Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.
Decay of the HIV reservoir is slowed over time in part by expansion of the pool of HIV-infected cells. This expansion reflects homeostatic proliferation of infected cells by interleukin-7 (IL-7) or antigenic stimulation, as well as new rounds of infection of susceptible target cells. As novel therapies are being developed to accelerate the decay of the latent HIV reservoir, it will be important to identify interventions that prevent expansion and/or repopulation of the latent HIV reservoir. Our previous studies showed that HIV protease cleaves the host protein procaspase 8 to generate Casp8p41, which can bind and activate Bak to induce apoptosis of infected cells. In circumstances where expression of the anti-apoptotic protein BCL2 is high, Casp8p41 instead binds BCL2, and cell death does not occur. This effect can be overcome by treating cells with the clinically approved BCL2 antagonist venetoclax, which prevents Casp8p41 from binding BCL2, thereby allowing Casp8p41 to bind Bak and kill the infected cell. Here we assess whether the events that maintain the HIV reservoir are also antagonized by venetoclax. Using the J-Lat 10.6 model of persistent infection, we demonstrate that proliferation and HIV expression are countered by the use of venetoclax, which causes preferential killing of the HIV-expressing cells. Similarly, during new rounds of infection of primary CD4 T cells, venetoclax causes selective killing of HIV-infected cells, resulting in decreased numbers of HIV DNA-containing cells.IMPORTANCECure of HIV infection requires an intervention that reduces the HIV reservoir size. A variety of approaches are being tested for their ability to impact HIV reservoir size. Even if successful, however, these approaches will need to be combined with additional complementary approaches that prevent replenishment or repopulation of the HIV reservoir. Our previous studies have shown that the FDA-approved BCL2 antagonist venetoclax has a beneficial effect on the HIV reservoir size following HIV reactivation. Here we demonstrate that venetoclax also has a beneficial effect on HIV reservoir size in a model of homeostatic proliferation of HIV as well as in acute spreading infection of HIV in primary CD4 T cells. These results suggest that venetoclax, either alone or in combination with other approaches to reducing HIV reservoir size, is a compound worthy of further study for its effects on HIV reservoir size.
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Nathan W
NW
Cummins
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Amy M
AM
Sainski-Nguyen
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Sekar
S
Natesampillai
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Fatma
F
Aboulnasr
Department of Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Oncology Research, Mayo Clinic, Rochester, Minnesota, USA.
Scott
S
Kaufmann
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA Badley.andrew@mayo.edu.
Andrew D
AD
Badley
D017209:Apoptosis; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology*; D016923:Cell Death; D002478:Cells, Cultured; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D019169:Jurkat Cells; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D017735:Virus Latency; D014779:Virus Replication
D019086:Bridged Bicyclo Compounds, Heterocyclic; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; C579720:venetoclax
Bcl-2 family; HIV; antiapoptosis; reservoir